suramab, a new pharmaceutical compound with antiangiogenic effects
- 总结
- This can be seen in the patent file
- 技术优势
- Suramab is the brand name of a new combination of drugs made up of suramin and bevacizumab. Suramab has antiangiogenic properties that can be applied to oncological and ophthalmological diseases.
The european patent (EP 2186529 B1) was granted in March 2012.
The US patent is still pending
- 申请号码
- MX2008000104
- 覆盖范围
- Great Britain, Ireland, Sweden, Denmark, The Netherland, Germany, Spain, France
- 商品和服务
- License agreement
- 专利信息
- Issued patent
- 国家/地区
- 阿根廷
欲了解更多信息，请点击 这里
